Androgen Insensitivity Syndrome News and Articles
Return to Library
What is androgen insensitivity syndrome?
Androgen insensitivity syndrome is a condition that affects sexual development before birth and during puberty. People with this condition are genetically male, with one X and one Y chromosome. Because their bodies are unable to respond to certain hormones (called androgens), they may have mostly female sexual characteristics or signs of both male and female sexual development (hermaphroditism).
Complete androgen insensitivity syndrome occurs when the body cannot use androgens at all. Partial or mild androgen insensitivity syndrome results when tissues are partially sensitive to the effects of androgens. People with partial androgen insensitivity (also called Reifenstein syndrome) can have normal female sexual characteristics, both male and female sexual characteristics, or normal male sexual characteristics. People with mild androgen insensitivity appear male, but are often infertile and tend to develop female breasts at puberty.
How common is androgen insensitivity syndrome?
Complete androgen insensitivity syndrome affects 2 to 5 per 100,000 live male births. Partial androgen insensitivity is at least as common as complete androgen insensitivity. Mild androgen insensitivity is much less common.
What genes are related to androgen insensitivity syndrome?
Mutations in the AR gene cause androgen insensitivity syndrome.
The AR gene provides instructions to make a protein called an androgen receptor. This protein allows cells to respond to androgens, which are hormones (such as testosterone) that direct male sexual development. Androgens and androgen receptors also have other important functions in both males and females, such as regulating hair growth and sex drive. Mutations in the AR gene prevent the androgen receptor from working properly, which makes cells less responsive to androgens or prevents cells from using these hormones at all. Depending on the level of androgen insensitivity, an affected person's sexual characteristics can vary from mostly female to mostly male.
How do people inherit androgen insensitivity syndrome?
This condition is inherited in an X-linked recessive pattern. A condition is considered X-linked if the mutated gene that causes the disorder is located on the X chromosome, one of the two sex chromosomes. In males (who have only one X chromosome) one altered copy of the gene in each cell is sufficient to cause the condition. Males are affected by X-linked recessive disorders much more frequently than females. A striking characteristic of X-linked inheritance is that fathers cannot pass X-linked traits to their sons.
About two-thirds of cases are inherited from mothers who carry an altered copy of the AR gene on one of their two X chromosomes. The remaining cases result from a new mutation in a mother's egg cell before the child is conceived.
Source: National Institutes of Health
Recent Androgen Insensitivity Syndrome News and Articles
Investigators at University Hospital Center Release New Data on Androgen-Insensitivity Syndrome
2011 NOV 23 -- According to the authors of recent research from Montpellier, France, "46, XY disorders of sex differentiation (46, XY DSD) can be due to a
testis determination defect, an
androgen biosynthesis defect, or androgen resistance (complete or partial androgen insensitivity
syndrome (PAIS), or 5 alpha reductase deficiency). We aimed to evaluate the impact of a prenatal
contamination by environmental xenoestrogens in 'idiopathic' PAIS-like
phenotype."
"We investigated 28 newborn/infant males with 46, XY DSD, normal androgen production, and no androgen receptor or steroid-5 alpha R type II enzyme (SRD5A2) gene mutations. To exclude other genetic defects, we sequenced the steroidogenic factor 1 (SF1) and mastermind-like domain-containing 1 (MAMLD1) genes, which were recently found to be associated with the PAIS-like phenotype. Parents were interviewed about their environmental/occupational exposure to endocrine disrupting chemicals (EDCs) before/during the patients' fetal life. Total estrogenic bioactivity of patient serum was analyzed by ultrasensitive bioassay. All the patients had normal SF1 sequence and one patient showed a double polymorphism of MAMLD1. Eleven (39.3%) of the 28 patients had reported parental fetal exposure to EDCs. The mean estrogenic bioactivity in these 11 patients with fetal EDC exposure (6.65 +/- 8.07 pg/ml) versus 17 cases without contamination (1.27 +/- 0.34 pg/ml) and controls (1.06 +/- 0.44 pg/ml; P<0.05) was elevated," wrote L. Gaspari and colleagues, University Hospital Center.
The researchers concluded: "Our results indicate that the 'idiopathic' PAIS-like phenotype may in some cases be related to EDC contamination during fetal life."
Gaspari and colleagues published their study in European Journal of Endocrinology ('Idiopathic' partial androgen insensitivity syndrome in 28 newborn and infant males: impact of prenatal exposure to environmental endocrine disruptor chemicals' European Journal of Endocrinology, 2011;165(4):579-587).
For additional information, contact L. Gaspari, CHU Montpellier, Hopital Lapeyronie, Service Chirurg Pediatrics, Montpellier, France.
Publisher contact information for the European Journal of Endocrinology is: Bioscientifica Ltd, Euro House, 22 Apex Court Woodlands, Bradley Stoke, Bristol BS32 4JT, England.
Keywords: City:Montpellier, Country:France, Region:Europe, Hormones, Chemistry, Endocrine Research, Pseudohermaphroditism, Congenital Abnormalities, Male Urogenital Diseases, Urogenital Abnormalities, X-Linked Genetic Diseases, Sex Differentiation Disorders, Androgen-Insensitivity Syndrome, Androgens and Anabolic Steroids
This article was prepared by Biotech Week editors from staff and other reports. Copyright 2011, Biotech Week via NewsRx.com.